On Feb. 28, 2024, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor (11 to 1; 1 abstain) to recommend that individuals aged 65 and older should receive an additional dose of 2023-2024 Formula COVID-19 vaccine at least four months after the initial 2023-2024 COVID-19 dose.

ACIP’s recommendation was subsequently endorsed by the CDC. Doses of the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) are available at major retail pharmacies nationwide and can be ordered through one of our distribution partners for physician use in the non-retail setting.

While this recommendation focuses on protection for older adults who are at increased risk of COVID-19, information shared at the ACIP meeting also reinforces the ongoing benefit of vaccination for all those who are eligible. Data from clinical trials continue to show broad long-lived neutralization responses to currently circulating forward-drift variants including JN.1 and JN.4 for our protein-based non-mRNA COVID-19 vaccine, while maintaining a favorable side effect profile. Peer-reviewed real-world effectiveness data is being published that shows the immune responses seen in our trials translates into COVID-19 prevention in the real world.

Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. Refer to the full Fact Sheet for information about the Novavax COVID-19 Vaccine, Adjuvanted.

The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.